Cardiovascular risks associated with dipeptidyl peptidase-4 inhibitors monotherapy compared with other antidiabetes drugs in the Japanese population: A nationwide cohort study.
Maki KomamineKazuhiro KajiyamaChieko IshiguroYoshiaki UyamaPublished in: Pharmacoepidemiology and drug safety (2019)
Risk of MI and HF requiring hospitalization associated with DPP-4Is as monotherapy was significantly higher than BGs, significantly lower than SUs, and similar to α-GIs.